Breast Cancer in the Post-Genomic Era (eBook)
XI, 230 Seiten
Springer New York (Verlag)
978-1-60327-945-1 (ISBN)
Breast Cancer is the most common tumor in women and the second leading cause of cancer deaths worldwide. Due to breakthroughs in gene profiling, the knowledge of the pathophysiology of the mammary gland had greatly increased over the last decade. In Breast Cancer in the Post Genomic Era, Antonio Giordano, Nicola Normanno, and a panel of international authorities in their field provide a comprehensive approach to the biology, diagnosis, prevention, and treatment of human breast carcinoma.
The book provides a comprehensive approach to breast cancer, describing the use of gene profiling techniques to distinguish specific features of individual carcinomas, as well as emerging novel therapeutic approaches to treatment. Additional chapters cover the use of transgenic mice to model human breast cancer and the role of the EGF-CFC family in mammary gland development and neoplasia. Breast Cancer in the Post Genomic-Era succeeds in looking at breast cancer pathogenesis, diagnosis, and treatment under a more comprehensive light, and is a valuable resource for any Radiation or Surgical Oncologist, Cancer Biologist or Pathologist.
Breast Cancer is the most common tumor in women and the second leading cause of cancer deaths worldwide. Due to breakthroughs in gene profiling, the knowledge of the pathophysiology of the mammary gland had greatly increased over the last decade. In Breast Cancer in the Post Genomic Era, Antonio Giordano, Nicola Normanno, and a panel of international authorities in their field provide a comprehensive approach to the biology, diagnosis, prevention, and treatment of human breast carcinoma.The book provides a comprehensive approach to breast cancer, describing the use of gene profiling techniques to distinguish specific features of individual carcinomas, as well as emerging novel therapeutic approaches to treatment. Additional chapters cover the use of transgenic mice to model human breast cancer and the role of the EGF-CFC family in mammary gland development and neoplasia. Breast Cancer in the Post Genomic-Era succeeds in looking at breast cancer pathogenesis, diagnosis, and treatment under a more comprehensive light, and is a valuable resource for any Radiation or Surgical Oncologist, Cancer Biologist or Pathologist.
Preface 6
Contents 8
Contributors 10
1 The Genomic Basis of Breast Development and Differentiation 13
1. ARCHITECTURE OF THE HUMAN BREAST 13
2. CELL PROLIFERATION AND STEROID RECEPTOR CONTENT IN THE NORMAL BREAST 14
3. INFLUENCE OF AGE AND PARITY ON BREAST DEVELOPMENT AND CANCER SUSCEPTIBILITY 14
4. BREAST DEVELOPMENT AND THE PATHOGENESIS OF BREAST CANCER 15
5. GENOMIC APPROACH TO UNDERSTAND BREAST CANCER SUSCEPTIBILITY 17
6. CONCLUDING REMARKS 24
REFERENCES 25
2 Mammary Glands, Stem Cells, and Breast Cancer 31
1. BREAST DEVELOPMENTAL BIOLOGY AND TUMORIGENESIS 31
2. STEM CELL BIOLOGY IN THE MAMMARY GLAND 38
3. INFLUENCE OF THE MICROENVIRONMENT ON STEM CELL BIOLOGY AND CANCER 42
4. CLOSING REMARKS 46
REFERENCES 46
3 The Genetics of Breast Cancer: Application in Clinical Practice 51
Summary 51
1. INTRODUCTION 52
2. SPORADIC BREAST CANCER 52
3. HEREDITARY BREAST CANCER 56
REFERENCES 61
4 Alterations in Cell Cycle Regulatory Genes in Breast Cancer 67
1. CELL CYCLE: AN OVERVIEW 68
2. BREAST CANCER AND CELL CYCLE 79
REFERENCES 86
5 Neuregulins in the Nucleus 90
1. INTRODUCTION 90
2. OBSERVATIONS ON NRG IN THE NUCLEUS 91
3. NRG EXPERIMENTS 92
4. NRG FUNCTIONS IN THE NUCLEUS 93
REFERENCES 95
6 Role of the EGF-CFC Family in Mammary Gland Development and Neoplasia 98
1. EGF-CFC PROTEIN FAMILY: STRUCTURE AND POSTTRANSLATIONAL MODIFICATIONS 99
2. SIGNALING PATHWAYS ACTIVATED OR INHIBITED BY CRIPTO-1 101
3. NODAL/ALK4/ALK7/SMAD-2 SIGNALING PATHWAY 102
4. GLYPICAN-1/C-SRC/MAPK/AKT SIGNALING PATHWAY 103
5. CRIPTO-1 AND THE WNT SIGNALING PATHWAY 103
6. FUNCTION AND EXPRESSION OF EGF-CFC PROTEIN FAMILY DURING EMBRYONIC DEVELOPMENT 104
7. EGF-CFC PROTEINS IN MAMMARY GLAND DEVELOPMENT 104
8. CRIPTO-1 IN TRANSFORMATION AND TUMORIGENESIS OF MAMMARY EPITHELIUM 105
9. EXPRESSION OF CR-1 IN HUMAN BREAST CARCINOMAS 106
10. CONCLUSIONS 108
REFERENCES 108
7 Modeling Human Breast Cancer: The Use of Transgenic Mice 114
1. PROMOTERS 115
3. CONCLUSIONS 124
REFERENCES 125
8 Gene Expression Profiling in Breast Cancer: Clinical Applications 133
1. INTRODUCTION 133
2. MOLECULAR CLASSIFICATION 136
3. DIAGNOSIS AND PROGNOSIS 138
4. GENE EXPRESSION PROFILING FOR PREDICTION OF RESPONSE TO THERAPY 139
5. INTEGRATED DATA ANALYSIS OF MICROARRAY PLATFORMS 141
6. CONCLUSIONS 141
REFERENCES 143
9 TGF- b Signaling: A Novel Target for Treatment of Breast Cancer? 147
1. INTRODUCTION 147
2. THE TGF- ß SIGNALING PATHWAY 148
3. EFFECTS OF TGF- ß ON BREAST CANCER BIOLOGY 148
4. DICHOTOMY OF TGF- ß SIGNALING 153
5. TGF- ß AS A TARGET FOR BREAST CANCER THERAPY 154
REFERENCES 156
10 DNA Methylation in Breast Cancer 160
1. CHROMATIN, ITS MODIFICATIONS, AND CANCER 160
2. THE DNA METHYLATION PATTERN 162
3. MECHANISMS OF SILENCING OF GENE EXPRESSION BY DNA METHYLATION 163
4. DNA METHYLATION AND DEMETHYLATION ENZYMES 164
5. BILATERAL RELATIONSHIP BETWEEN CHROMATIN AND DNA METHYLATION 169
6. ABERRATIONS IN DNA METHYLATION IN BREAST CANCER 170
7. HYPERMETHYLATION OF GENES IN BREAST CANCER, ROLE IN SILENCING TUMOR SUPPRESSOR GENES 171
8. THERAPEUTIC IMPLICATION OF HYPERMETHYLATION OF GENES IN BREAST CANCER 172
9. HYPOMETHYLATION IN BREAST CANCER AND ITS THERAPEUTIC IMPLICATIONS 173
10. CONCLUSIONS AND PROSPECTIVE 176
REFERENCES 177
11 Signal Transduction Inhibitors in the Treatment of Breast Cancer 185
1. INTRODUCTION 186
2. MOLECULAR TARGETS IN BREAST CANCER 186
3. ANTI-EGFR DRUGS IN BREAST CANCER 189
4. VEGFR SIGNALLING INHIBITORS IN BREAST CANCER 193
5. INHIBITORS OF INTRACELLULAR SIGNAL TRANSDUCTION PATHWAYS 195
6. ENDOCRINE THERAPY IN COMBINATION WITH SIGNALLING INHIBITORS 198
7. CONCLUSIONS 201
REFERENCES 202
12 Integration of Target-Based Agents in Current Protocols of Breast Cancer Therapy 210
1. INTRODUCTION 211
2. TARGETING ERBB RECEPTORS 212
3. TARGETING ANGIOGENESIS 221
4. TARGETING MTOR 223
5. CONCLUSIONS 226
REFERENCES 226
Index 232
Erscheint lt. Verlag | 22.6.2009 |
---|---|
Reihe/Serie | Current Clinical Oncology | Current Clinical Oncology |
Zusatzinfo | XI, 230 p. 13 illus., 10 illus. in color. |
Verlagsort | New York |
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Allgemeines / Lexika |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Chirurgie | |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik | |
Schlagworte | BRCA • Breast Cancer • Breast Cancer therapy • Carcinom • gene expression • Genomic Basis • Mammory Glands • surgical oncology • TGF-B Signaling |
ISBN-10 | 1-60327-945-8 / 1603279458 |
ISBN-13 | 978-1-60327-945-1 / 9781603279451 |
Haben Sie eine Frage zum Produkt? |
![PDF](/img/icon_pdf_big.jpg)
Größe: 2,7 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich